Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ceapro has entered into a research and development collaboration agreement with the National Research Council of Canada (NRC), which is expected to be undertaken at the NRC Institute for Nutrisciences and Health (INH) in Charlottetown, Prince Edward Island.
Subscribe to our email newsletter
Ceapro said that studies on its core ingredients including avenanthramides, beta glucan, and peptides are expected to be completed over the next year, as per the terms of the partnership agreement.
Ceapro is expected to work with the NRC-INH in Charlottetown PEI to complete several in-vitro and ex-vivo assays on the current suite of Ceapro products as well as prototype samples of new products, which are expected to provide valuable data to support the sales and marketing of Ceapro products.
David Fielder, chief scientific officer of Ceapro, said: “This is an exciting time for Ceapro and we expect to have completed these assays over the next year. Several of these assays are expected to target new high value therapeutic indications that can enhance the value of our products and we are very excited to be part of this collaboration.”
Ceapro said that PEI is supporting this collaboration with a repayable contribution of $100,000 and the Atlantic Canada Opportunities Agency is providing a non repayable contribution of $50,000. Ceapro has leased lab space in the NRC-INH facility in support of this collaboration and future product development work.